Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2019

Open Access 01-12-2019 | Gout | Research article

Prevalence and incidence of non-gout crystal arthropathy in southern Sweden

Authors: Mohaned Hameed, Aleksandra Turkiewicz, Martin Englund, Lennart Jacobsson, Meliha C. Kapetanovic

Published in: Arthritis Research & Therapy | Issue 1/2019

Login to get access

Abstract

Objective

To estimate the prevalence and incidence of non-gout crystal arthropathy in relation to socioeconomic factors in southern Sweden.

Methods

All patients (age ≥ 18 years) with at least one visit to a physician with the diagnosis of interest in the Skåne region (population of 1.3 million) in 1998–2014 were identified. Non-gout crystal arthropathy (ICD-10 codes M11.0–M11.9) was subclassified in four different groups: calcium pyrophosphate crystal deposition related arthropathy (CPPD), unspecified non-gout arthropathies, chondrocalcinosis, and hydroxyapatite crystal deposition disease. The crude and age-adjusted point prevalence on December 31, 2014, and the cumulative incidence during 2014 were calculated for all non-gout crystal arthropathies, CPPD, and other unspecified non-gout arthropathies overall and in relation to occupation, income, and level of education.

Results

The crude 2014 point prevalence (95% CI) and 2014 cumulative incidence (95% CI) of all non-gout crystal arthropathies were 0.23% (0.23–0.24) and 21.5 (19–25) cases/100,000 persons. Mean age (range) among all prevalent cases in 2014 was 71 (20–102) years and 56% were males. The point prevalence and cumulative incidence of CPPD were 0.09% (0.08–0.09) and 8 (7–10)/100,000 persons, respectively. The corresponding data for unspecified non-gout crystal deposition disease was 0.16% (0.16–0.17) and 15.6 (13–18)/100,000 persons, respectively. The prevalence and incidence of CPPD and unspecified non-gout crystal arthropathies were slightly higher in men and increased with age irrespective of gender. Unspecified non-gout crystal arthropathy but not CPPD was less prevalent in persons with ≥ 15 years of education, whereas there were no clear associations with occupation and income.

Conclusion

The prevalence of all diagnosed non-gout crystal arthropathies was 0.23%, thus considerably less prevalent than gout in southern Sweden. CPPD and other unspecified non-gout crystal arthropathies are the predominant diagnoses, increasing with age and in men. With the exception for unspecified non-gout crystal arthropathies being inversely correlated to a higher level of education, no convincing association with the socioeconomic factors was found.
Literature
1.
go back to reference Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563–70.CrossRef Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563–70.CrossRef
2.
go back to reference Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575–84.CrossRef Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575–84.CrossRef
3.
go back to reference Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham study. J Rheumatol. 1989;16(9):1241–5.PubMed Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham study. J Rheumatol. 1989;16(9):1241–5.PubMed
4.
go back to reference Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711–5.CrossRef Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711–5.CrossRef
5.
go back to reference Reginato AJ, Hollander JL, Martinez V, et al. Familial chondrocalcinosis in the Chiloe Islands, Chile. Ann Rheum Dis. 1975;34:260–8.CrossRef Reginato AJ, Hollander JL, Martinez V, et al. Familial chondrocalcinosis in the Chiloe Islands, Chile. Ann Rheum Dis. 1975;34:260–8.CrossRef
6.
go back to reference Zhang Y, Johnson K, Russell RG, et al. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5’-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 2005;52:1110–7.CrossRef Zhang Y, Johnson K, Russell RG, et al. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5’-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 2005;52:1110–7.CrossRef
7.
go back to reference Williams CJ, Pendleton A, Bonavita G, et al. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2003;48:2627–31.CrossRef Williams CJ, Pendleton A, Bonavita G, et al. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2003;48:2627–31.CrossRef
9.
go back to reference Zhang W, Neame R, Doherty S, et al. Relative risk of knee chondrocalcinosis in siblings of index cases with pyrophosphate arthropathy. Ann Rheum Dis. 2004;63:969–73.CrossRef Zhang W, Neame R, Doherty S, et al. Relative risk of knee chondrocalcinosis in siblings of index cases with pyrophosphate arthropathy. Ann Rheum Dis. 2004;63:969–73.CrossRef
10.
go back to reference Bergstrom G, Bjelle A, Sundh V, et al. Joint disorders at ages 70, 75 and 79 years—a cross-sectional comparison. Br J Rheumatol. 1986;25:333–41.CrossRef Bergstrom G, Bjelle A, Sundh V, et al. Joint disorders at ages 70, 75 and 79 years—a cross-sectional comparison. Br J Rheumatol. 1986;25:333–41.CrossRef
11.
go back to reference Neame RL, Carr AJ, Muir K, et al. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513–8.CrossRef Neame RL, Carr AJ, Muir K, et al. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513–8.CrossRef
13.
go back to reference Garcia GM, McCord GC, Kumar R. Hydroxyapatite crystal deposition disease. Semin Musculoskelet Radiol. 2003;7(3):187–93.CrossRef Garcia GM, McCord GC, Kumar R. Hydroxyapatite crystal deposition disease. Semin Musculoskelet Radiol. 2003;7(3):187–93.CrossRef
15.
go back to reference Rush PJ, Wilmot D, Shore A. Hydroxyapatite deposition disease presenting as calcific periarthritis in a 14-year-old girl. Pediatr Radiol. 1986;16(2):169–70.CrossRef Rush PJ, Wilmot D, Shore A. Hydroxyapatite deposition disease presenting as calcific periarthritis in a 14-year-old girl. Pediatr Radiol. 1986;16(2):169–70.CrossRef
16.
go back to reference Musacchio E, Ramonda R, Perissinotto E, et al. The impact of knee and hip chondrocalcinosis on disability in older people: the ProVA study from northeastern Italy. Ann Rheum Dis. 2011;70(11):1937–43.CrossRef Musacchio E, Ramonda R, Perissinotto E, et al. The impact of knee and hip chondrocalcinosis on disability in older people: the ProVA study from northeastern Italy. Ann Rheum Dis. 2011;70(11):1937–43.CrossRef
20.
go back to reference Neogi T, Nevitt M, Niu J, et al. Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum. 2006;54:1822–8.CrossRef Neogi T, Nevitt M, Niu J, et al. Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum. 2006;54:1822–8.CrossRef
21.
go back to reference Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. the MAPPING study. Clin Exp Rheumatol. 2005;23:819–28.PubMed Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. the MAPPING study. Clin Exp Rheumatol. 2005;23:819–28.PubMed
22.
go back to reference Ryu K, Iriuchishima T, Oshida M, et al. The prevalence of and factors related to calcium pyrophosphate dihydrate crystal deposition in the knee joint. Osteoarthr Cartil. 2014;22(7):975–9.CrossRef Ryu K, Iriuchishima T, Oshida M, et al. The prevalence of and factors related to calcium pyrophosphate dihydrate crystal deposition in the knee joint. Osteoarthr Cartil. 2014;22(7):975–9.CrossRef
23.
go back to reference Balderrama CK, Rosenthal AK, Lans D, et al. Calcium pyrophosphate deposition disease and associated medical co-morbidities: a national cross-sectional study of US veterans. Arthritis Care Res. 2017;69(9):1400–6.CrossRef Balderrama CK, Rosenthal AK, Lans D, et al. Calcium pyrophosphate deposition disease and associated medical co-morbidities: a national cross-sectional study of US veterans. Arthritis Care Res. 2017;69(9):1400–6.CrossRef
24.
go back to reference Jaccard YB, Gerster JC, Calame L. Mixed monosodium urate and calcium pyrophosphate crystal-induced arthropathy. A review of seventeen cases. Rev Rhum Engl Ed. 1996;63(5):331–5.PubMed Jaccard YB, Gerster JC, Calame L. Mixed monosodium urate and calcium pyrophosphate crystal-induced arthropathy. A review of seventeen cases. Rev Rhum Engl Ed. 1996;63(5):331–5.PubMed
25.
go back to reference Kapetanovic MC, Hameed M, Turkiewicz A, et al. Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective. RMD Open. 2016;2(2):e00032.CrossRef Kapetanovic MC, Hameed M, Turkiewicz A, et al. Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective. RMD Open. 2016;2(2):e00032.CrossRef
26.
go back to reference Dehlin M, Stasinopoulou K, Jacobsson LTH. Validity of gout diagnosis in Swedish primary and secondary care. BMC Musculoskelet Disord. 2015;16:149.CrossRef Dehlin M, Stasinopoulou K, Jacobsson LTH. Validity of gout diagnosis in Swedish primary and secondary care. BMC Musculoskelet Disord. 2015;16:149.CrossRef
Metadata
Title
Prevalence and incidence of non-gout crystal arthropathy in southern Sweden
Authors
Mohaned Hameed
Aleksandra Turkiewicz
Martin Englund
Lennart Jacobsson
Meliha C. Kapetanovic
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2019
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-019-2077-6

Other articles of this Issue 1/2019

Arthritis Research & Therapy 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.